AsianFin -- Isomorphic Labs, the drug discovery company spun out of DeepMind in 2021, is preparing to begin human clinical trials of its first AI-designed drugs.

Positioned at the forefront of integrating artificial intelligence into pharmaceutical research, Isomorphic Labs uses advanced machine learning algorithms to analyze vast biological datasets, identify potential drug targets, and design novel compounds aimed at treating a range of diseases.